
To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)—Market-Insight,-Epidemiology-and-Market-Forecast-2027
Oct 22, 2018 | Reading Time: < 1 minute
To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)—Market-Insight,-Epidemiology-and-Market-Forecast-2027
FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...
Find MoreOctober, worldwide, is designated as the Breast cancer awareness month. Pink ribbons. Pink colored tee-shirts. Pink banners. Going pink, wearing pink - the whole month is devoted to raising awareness about breast cancer in women. Healthcare institutions, pharmaceutical companies, and federations all over dedicatedl...
Find MoreAZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi ...
Find MorePenetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Join Up Now!Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.